Compare TG Therapeutics Inc (TGTX) vs Viasat (VSAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Viasat — how do they compare? TG Therapeutics Inc trades at $54.76 (market cap $8.16B), while Viasat trades at $71.63 (market cap $9.29B). The key difference: TG Therapeutics Inc and Viasat are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Viasat nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Viasat for 7 Days on average.
| TGTX | VSAT | |
|---|---|---|
Market Cap | $8.16B | $9.29B |
Volume | 1,735,121 | 2,084,105 |
Sector | Health | Technology |
52-Week High | $59.06 | $89.81 |
52-Week Low | $26.94 | $30.35 |
Typical Hold Time | 16 Days | 7 Days |
Enterprise Value | $8.37B | $14.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Viasat
Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →
